[Evaluation of teratogenic risk: the contribution of abnormalities registries].
Birth defects registries have been established following the thalidomide epidemic in the early sixties. A first objective of registries is to monitor the frequency of specific malformations in order to detect as early as possible any variation caused by the introduction of a new teratogen in the environment. After 30 years not any new teratogen has been identified by this. It appears that the predictive value of alarms generated by surveillance is extremely low and that resources are insufficient to investigate most of warnings. However, registries have been useful to test specific hypotheses i.e. the effect of iatrogenic exposures. Three examples are given, showing the necessary characteristics of registries: topical treatment with tretinoin, chorionic biopsy and cancer treatment.
Département des Sciences de la Santé Communautaire, Centre Hospitalier Universitaire, Université de Sherbrooke, Canada.
P
P
De Wals
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000970:Antineoplastic Agents / Q000009:adverse effects; D015193:Chorionic Villi Sampling / Q000009:adverse effects; D000013:Congenital Abnormalities / Q000209:etiology*; D005260:Female; D006801:Humans; D007049:Iatrogenic Disease; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011237:Predictive Value of Tests; D011247:Pregnancy; D012307:Risk Factors; D014212:Tretinoin / Q000009:adverse effects
D000970:Antineoplastic Agents; D014212:Tretinoin
Evaluation des risques tératogènes: l'apport des registres de malformations.